Remepy develops Hybrid Drugs that integrate prescription medicines with personalized, AI-driven therapeutic apps to combine pharmacology with adaptive physical, cognitive, and behavioral interventions. The company partners with pharmaceutical firms to co-develop these drug–software combination products and recently announced a strategic collaboration with Merck KGaA. Remepy’s lead program, Hybridopa for Parkinson’s disease, produced encouraging Phase IIa results supported by peer‑reviewed publications and is being prepared for a global Phase III trial expected to begin in Q4 2026. The Series A financing and existing investor base have brought total capital raised to $62 million, providing funds to expand the company’s pipeline, platform, and pharmaceutical partnerships. Remepy positions its approach within emerging FDA frameworks for drug‑software combination products and aims to create new IP and lifecycle-management opportunities for partner drugs.

Total raised

$46M

Funding rounds

3

Latest round

Series A

Latest activity

Aug 2026